Chengming et al. revealed that KRAS-mutated NSCLC exhibited an inflammatory phenotype to adaptive immune tolerance, indicated via higher tumor mutational burden (TMB) and a higher percentage for CD8+ tumor-infiltrating lymphocytes (TILs) [140]. This evidence concerns the gene KRAS and neoplasm.